Riluzole may be an effective treatment for cerebellar ataxia, say researchers who call for further studies to confirm their findings. The 1-year trial showed that patients with hereditary cerebellar ...

Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the ...

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the ...

Only successful pivotal Phase III trial in Ataxia-Telangiectasia (A-T), a rare, progressive neurodegenerative disease with no approved treatments Phase III trial successfully achieved its primary ...

IntraBio Inc. today announced that results from its pivotal Phase III clinical trial evaluating levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T) have been published in The Lancet ...

- Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. - Troriluzole has been granted Fast-Track, Orphan Drug Designation (ODD) and ...

Treatment goals for Friedreich ataxia include symptom management, slowing disease progression, and enhancing quality of life through multidisciplinary care. Supportive therapies address comorbidities ...

The company is expected to announce clinical data for hard-to-treat epilepsy and obesity later this year.

Friedreich's ataxia (FA) is a rare but devastating genetic disorder. Those with the condition are often diagnosed between 5 and 15 years of age and live only into their 30s or 40s. There is no widely ...

Published in the open-access journal Ferroptosis and Oxidative Stress, the review by Giovanni Cravin and Giorgio Cozza from ...